AI assistant
Tempest Therapeutics, Inc. — Director's Dealing 2016
Sep 13, 2016
34632_dirs_2016-09-12_36313a44-90c7-46c4-9e76-94573f020987.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2016-09-08
Reporting Person: Couturier Christophe (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-09-08 | Common Stock | A | 50000 | — | Acquired | 50600 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-09-08 | Stock Option (right to buy) | $7.15 | A | 200000 | Acquired | 2026-09-08 | Common Stock (200000) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents the right to receive one share of common stock upon vesting. The RSU vests as to 25% of the shares on September 6, 2017 and as to an additional 6.25% of the shares each successive three-month period thereafter, until September 6, 2020.
F2: Represents 600 shares of common stock and 50,000 RSUs.
F3: The option vests as to 25% of the option shares on September 6, 2017 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.